BioSpace News Archive

Genetown

Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer

Verastem Oncology announced new results from the first-ever global LGSOC Patient Impact Survey, developed with patient advocates and community medical leaders to better understand and address the complex needs and experiences of those living with low-grade serous ovarian cancer.

March 18, 2024
·
7 min read
Business

Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights

Tango Therapeutics, Inc., a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided business highlights.

March 18, 2024
·
15 min read
BioMidwest

Avenacy Announces New Product Launches and Participation in DCAT Week 2024

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced it has launched Fosaprepitant for Injection and Fulvestrant Injection in the United States.

March 18, 2024
·
4 min read
Drug Development

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. announced it has appointed Dr. James “Jim” Kelly, Neurologist, as its Chief Medical Officer, to oversee its upcoming Phase II clinical trial.

March 18, 2024
·
6 min read
Business

Lucas Vitale Joins Orthofix as Chief People and Business Operations Officer

Orthofix Medical Inc., a leading global spine and orthopedics company, announced that Lucas Vitale has joined the company in the newly created role of Chief People and Business Operations Officer.

March 18, 2024
·
5 min read
BioMidwest

SHINE Technologies to Exhibit at 7th Annual Theranostics World Congress

SHINE Technologies will showcase its innovative capabilities for producing non-carrier-added lutetium-177 (n.c.a Lu-177), a radioisotope used in targeted cancer treatments, at the 7th Theranostic World Congress (TWC), March 22-24 in Santiago, Chile.

March 18, 2024
·
2 min read
Biotech Bay

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

Mainz Biomed N.V. will host an educational webinar on Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options which is taking place on March 20, 2024.

March 18, 2024
·
5 min read
Drug Development

ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease

ZyVersa Therapeutics, Inc. announces Institutional Review Board (IRB) approval of the Phase 2a clinical trial protocol to evaluate the efficacy and safety of Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease.

March 18, 2024
·
4 min read
Business

CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas - March 18, 2024

CytomX Therapeutics, Inc. today announced that the first clinical candidate in its TCB agreement with Astellas has entered into GLP toxicology studies which triggers a $5 million payment to CytomX.

March 18, 2024
·
5 min read
Biotech Bay

Aquedeon Medical Announces First Patient Enrolled in the IDE Study of Duett(TM) Vascular Graft System

Aquedeon Medical, Inc. is pleased to announce a significant milestone with initiation of its investigational device exemption (IDE) clinical trial to study for the Duett(TM) Vascular Graft System.

March 18, 2024
·
2 min read